Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

Learn more about:
Related Clinical Trial
Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan’s Lipodystrophy Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula The Visceral Adiposity Measurement and Observation Study Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

Official Title

Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities

Brief Summary

      The purpose of this study is to learn whether changing from a type of anti-HIV drug called a
      protease inhibitor (PI) to another type of anti-HIV drug will help to lower the amount of
      fats or sugars in the blood.

      PIs have been effective at keeping HIV viral load (amount of HIV in the blood) down. However,
      some people who take PIs have higher than normal levels of fats and/or sugars in the blood.
      Doctors believe that switching to anti-HIV drugs that do not contain PIs will improve the
      abnormal side effects. This study will test 3 different combinations of non-PI drugs to see
      which may improve side effects while keeping viral loads low.

Detailed Description

      Protease inhibitor (PI)-containing antiretroviral regimens are potent suppressors of HIV
      replication. Increasingly, metabolic abnormalities such as hypercholesterolemia and
      triglyceridemia are associated with PI use, reasons cited for switching to PI-sparing
      regimens. Yet optimal switch regimens that take into account both improvements in side
      effects and continued virologic suppression have not been defined. This study will compare
      the effect on chemical metabolic abnormalities of switching to an all nucleoside regimen
      versus dual nucleoside plus nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy.
      Determining the effects of each regimen on chemical metabolic abnormalities and maintenance
      of virologic suppression will define which of the switch strategies being studied improves
      metabolic abnormalities without compromising viral suppression.

      Patients are stratified on the basis of fasting non-HDL cholesterol and triglyceride levels
      and on ritonavir- or nonritonavir-containing pre-entry PI regimens. Patients are assigned
      randomly to add to their pre-entry regimen 1 of the following 3 treatments: Arm A - ABC; Arm
      B - NVP; or Arm C - EFV.

      Patients discontinue pre-entry PIs after Day 14. Patients are followed to determine the
      effect of the maintenance regimens on fasting non-high-density lipoprotein (HDL),
      cholesterol, and triglycerides at Week 24. Fasting total cholesterol, HDL cholesterol, direct
      low-density lipoprotein, and triglycerides are measured at Weeks 12, 24, and 48. Fasting
      glucose, insulin, C-peptide, apolipoproteins A-1 and B, lipoprotein a, and homocysteine are
      measured at Weeks 24 and 48. Anthropometrics, body mass index, and body image are measured at
      Weeks 12, 24, and 48. HIV viral load is measured at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40,
      and 48. If HIV RNA stays below 200 copies/ml, therapy continues unchanged. If confirmed HIV
      RNA of 200 copies/ml or higher is found, an HIV genotype is obtained providing the viral load
      is sufficient to yield results, the best medical therapy is instituted (not supplied by the
      study), and off treatment/on study follow-up is continued. If patients are intolerant to a
      study drug, an alternate study drug (ABC, EFV, or NVP supplied by the study) is permitted and
      switched treatment/on study follow-up continued, or the best medical therapy is instituted
      (not supplied by the study), and off treatment/on study follow-up is continued. Patients are
      followed until the last patient enrolled has completed 48 weeks on study.

Study Phase

Phase 2

Study Type



HIV Infections


Abacavir sulfate, Lamivudine and Zidovudine


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Primary Completion Date

February 2002

Eligibility Criteria

        Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV infected.

          -  Are on their first combination of stable anti-HIV drugs (have not changed drugs for at
             least 6 months, except for reasons other than failing treatment or short interruptions
             of less than 7 days).

          -  Have 2 measurements of viral load (amount of HIV in the blood) during the 6 months
             before entering the study that are below 400 copies/ml by RT-PCR test or below 500
             copies/ml by branched DNA test, measured at least 8 weeks apart.

          -  Have a viral load below 50 copies/ml within 30 days prior to entry.

          -  Have a CD4 cell count of 200 copies/ml or higher within 60 days of study entry.

          -  Are receiving medications and/or medications at certain doses that might interfere
             with the study.

          -  Are at least 13 years old and have signed consent of parent or guardian if under 18
             years of age.

          -  Have a negative pregnancy test within 14 days of study entry, if a woman able to have

          -  Agree to use a barrier method of birth control, men and women, while receiving study
             drugs and for 3 months afterwards.

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Are receiving high doses of testosterone. Low doses are allowed if received for 60 or
             more days before entering the study with no plans to change the dose during the first
             24 weeks of the study.

          -  Have had treatment with any nonnucleoside reverse transcriptase inhibitor (NNRTI).

          -  Have had treatment with ABC.

          -  Are allergic to study drugs or any ingredient in them.

          -  Are pregnant or breast-feeding.

          -  Have used any HIV vaccine or drugs affecting the immune system within 30 days prior to
             entering the study.

          -  Have had systemic treatment for cancer within 30 days of entering the study.

          -  Have had systemic treatment with certain other drugs that may interfere with the study
             within 14 days of entering the study.

          -  Have a serious illness that required systemic treatment or a hospital stay unless
             treatment was completed at least 14 days prior to entering the study, or are on stable
             treatment, in the doctor's opinion, for at least 14 days prior to entering the study.

          -  Abuse drugs or alcohol.

          -  Have or suspect they have acute hepatitis within 30 days of entering the study.




13 Years - N/A

Accepts Healthy Volunteers



David Wohl, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID

ACTG A5103

Secondary IDs


Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Study Sponsor

David Wohl, Study Chair, 

Verification Date

January 2003